Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > Up to 11 cents on Frankfurt exchange
View:
Post by indaknownewfie on Mar 01, 2021 12:15pm

Up to 11 cents on Frankfurt exchange

According to somebody trustworthy over on CEO.ca
Comment by NeedAPool on Mar 01, 2021 12:41pm
Just over an hour and 15 minutes left to trade on the Frankfurt exchange. Current price is .0691 Euros which is .1057 CDN. Not too shabby! Now just need to chew through the never ending .085 and .09!!!!
Comment by GajjarDr on Mar 01, 2021 12:44pm
Yes, exactly !!!!
Comment by Gordie444 on Mar 01, 2021 12:52pm
do you think we will hit .10 today or tomorrow?
Comment by nocashnoluck on Mar 01, 2021 12:53pm
0.15 by friday 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities